What is kanamycin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Kanamycin

Kanamycin is a second-line injectable aminoglycoside antibiotic used specifically for drug-resistant tuberculosis, but it is now recognized as inferior to other aminoglycosides and should generally be avoided when alternatives are available. 1, 2, 3

Drug Classification and Mechanism

Kanamycin is a semi-synthetic aminoglycoside antibiotic derived from Streptomyces kanamyceticus 4. It works by binding to the prokaryotic ribosome, inhibiting bacterial protein synthesis, making it bactericidal against both Gram-positive and Gram-negative bacteria 4.

Clinical Role in Tuberculosis Treatment

Current Position in Treatment Guidelines

Kanamycin is classified as a second-line injectable drug reserved for patients with drug-resistant tuberculosis whose isolates demonstrate susceptibility to the agent 1. However, the 2019 ATS/CDC/ERS/IDSA guidelines explicitly recommend AGAINST using kanamycin or capreomycin when other therapies can be assembled to achieve five effective drugs (conditional recommendation, very low certainty in evidence) 2.

Why Kanamycin is Inferior

The most compelling evidence comes from a 2021 individual patient data meta-analysis of 12,030 patients from 25 countries 3:

  • Compared to amikacin: Kanamycin resulted in 6 fewer cures per 100 patients (95% CI, 4-8)
  • Compared to streptomycin: Kanamycin resulted in 7 fewer cures (95% CI, 5-8) and 5 more deaths per 100 patients (95% CI, 4-7)
  • Critically, patients treated with kanamycin did not fare better than patients receiving NO injectable drugs at all 3

Kanamycin was significantly inferior to streptomycin in every measured outcome, with lower treatment success rates and higher death rates 2.

Dosing and Administration

When kanamycin must be used (due to resistance patterns or drug availability):

Adults:

  • 15 mg/kg/day (maximum 1.0 g/day) intramuscular or intravenous
  • Given as single daily dose 5-7 days/week initially
  • Reduce to 2-3 times weekly after first 2-4 months or after culture conversion
  • For patients >59 years: reduce to 10 mg/kg/day (750 mg) 1

Children:

  • 15-30 mg/kg/day (maximum 1 g/day) as single daily dose 1

Renal impairment:

  • Reduce dosing frequency to 2-3 times weekly
  • Maintain dose at 12-15 mg/kg to preserve concentration-dependent bactericidal effect
  • Give after dialysis to facilitate directly observed therapy
  • Monitor serum drug concentrations 1

Significant Toxicities

Ototoxicity

  • Causes deafness but less vestibular dysfunction than streptomycin 1
  • High-frequency hearing loss reported in up to 24% of patients receiving related aminoglycosides 1
  • Risk increases with longer treatment duration and higher cumulative doses
  • More common with concurrent diuretic use 1

Nephrotoxicity

  • More nephrotoxic than streptomycin 1
  • Renal impairment seen in 8.7% of patients with related aminoglycosides 1
  • Higher frequency in patients with:
    • Initially elevated creatinine
    • Larger total doses
    • Concurrent nephrotoxic agents 1

Pregnancy

  • Absolutely contraindicated in pregnancy due to risk of fetal nephrotoxicity and congenital hearing loss 1

Critical Monitoring Requirements

Baseline:

  • Audiogram
  • Vestibular testing
  • Serum creatinine 1

Monthly:

  • Renal function assessment
  • Questioning about auditory/vestibular symptoms
  • Repeat audiogram if symptoms develop 1

Patients with severe hepatic disease require closer renal monitoring due to predisposition to hepato-renal syndrome 1

Cross-Resistance Pattern

There is nearly complete cross-resistance between kanamycin and amikacin, but most streptomycin-resistant strains remain susceptible to both 1. This resistance pattern is clinically important when selecting alternative agents.

Practical Clinical Implications

Given the evidence showing kanamycin's inferiority and the availability of more effective alternatives, when an injectable aminoglycoside is needed for MDR-TB and susceptibility testing supports its use, choose streptomycin or amikacin—not kanamycin 3. The widespread use of kanamycin (4,330 patients in the meta-analysis) despite its inferior outcomes represents a concerning pattern that should be reversed in clinical practice 3.

References

Guideline

treatment of tuberculosis.

MMWR Recommendations and Reports, 2003

Guideline

treatment of drug-resistant tuberculosis. an official ats/cdc/ers/idsa clinical practice guideline.

American Journal of Respiratory and Critical Care Medicine, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.